Novo Nordisk Settles False Claims Act Charges For $58.6 Million

Novo Nordisk Settles False Claims Act Charges For $58.6 Million

Novo Nordisk Inc. will pay $58.65 million to resolve federal claims that the company violated the False Claims Act by failing to comply with the FDA’s Risk Evaluation and Mitigation Strategy (REMS) for its Type II diabetes medication Victoza. The government claimed that some Novo Nordisk sales representatives gave information to physicians that created the false or misleading impression that the Victoza REMS-required message was erroneous, irrelevant, or unimportant. The complaint further alleges that Novo Nordisk failed to comply with the REMS by creating the false or misleading impression about the Victoza REMS-required risk message that violated provisions of the FDCA and led some physicians to be unaware of the potential risks when prescribing Victoza. [9/7/17]

Search